IP Library Granted Patent US 9,624,556
Granted Patent B2
US 9,624,556 · App. 14/797,381 · Granted Apr 18, 2017

Viral and viral associated miRNAs and uses thereof

Inventors: Itzhak Bentwich (Misgav, IL); Amir Avniel (Tel Aviv, IL); Yael Karov (Tel Aviv, IL); Ranit Aharonov (Tel Aviv, IL)
Assignee: Rosetta Genomics Ltd.
C12Q1/701C12N15/111C12N15/1131C12N2310/14C12N2310/141C12N2320/10C12N2320/30C12N2330/10C12N2710/16222C12Q2600/136
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,624,556
App. No.
14/797,381
Granted
Apr 18, 2017
Kind
B2
Abstract

Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.

Claims (19)

1. A nucleic acid selected from the group consisting of:

(a) the sequence of SEQ ID NO: 2015;

(b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a);

(c) a sequence at least 95% identical to (a) or (b); and

(d) the complement of one of the nucleic acids of (a)-(c), wherein the complement is identical in length to the one of the nucleic acids of (a)-(c);

wherein the nucleic acid comprises a non-naturally occurring nucleotide.

2. A probe comprising a heterologous sequence, wherein the heterologous sequence consists of a nucleic acid sequence selected from the group consisting of:

(a) the sequence of SEQ ID NO: 2015;

(b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a);

(c) a sequence at least 95% identical to (a) or (b); and

(d) the complement of one of the nucleic acids of (a)-(c), wherein the complement is identical in length to the one of the nucleic acids of (a)-(c).

3. The probe of claim 2 , wherein the probe comprises at least one of a non-naturally occurring nucleotide and a label.

4. The probe of claim 2 , wherein the probe is attached to a solid substrate.

5. The probe of claim 4 , wherein the solid substrate is a biochip.

6. A vector comprising a heterologous sequence, wherein the heterologous sequence consists of a nucleic acid sequence selected from the group consisting of:

(a) the sequence of SEQ ID NO: 2015;

(b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a);

(c) a sequence at least 95% identical to (a) or (b); and

(d) the complement of one of the nucleic acids of (a)-(c), wherein the complement is identical in length to the one of the nucleic acids of (a)-(c).

Assignments (1)
SECURITY INTEREST Recorded Dec 15, 2017
From: ROSETTA GENOMICS INC.; ROSETTA GENOMICS LTD; MINUET DIAGNOSTICS, INC.; CYNOGEN INC.
To: GENOPTIX, INC.
Reel/Frame 044899/0237 →
Continuity (10)
Division 13887506 · May 6, 2013
Division 12850091 · Aug 4, 2010
Division 11511035 · Aug 28, 2006
Continuation In Part PCTIB2005002352 · May 26, 2005
Continuation In Part 10709739 · May 26, 2004
Provisional Application 60522459 · Oct 4, 2004
Provisional Application 60665094 · Mar 25, 2005
Provisional Application 60522450 · Oct 3, 2004
Provisional Application 60522451 · Oct 3, 2004
Related Publication 20160047004A1 · Feb 18, 2016